SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-23-001360 to 23andMe Holding Co. (ME) (CIK 0001804591)

23andMe Holding Co. (ME) (CIK 0001804591)
Date: Feb. 9, 2023 · CIK: 0001804591 · Accession: 0000000000-23-001360

AI Filing Summary & Sentiment

File numbers found in text: 333-269595

Date
February 9, 2023
Author
Not clearly detected
Form
UPLOAD
Company
23andMe Holding Co. (ME) (CIK 0001804591)

Letter

United States securities and exchange commission logo February 9, 2023 Kathy Hibbs Chief Administrative Officer 23andMe Holding Co. 349 Oyster Point Boulevard South San Francisco, California 94080 Re:23andMe Holding Co. Registration Statement on Form S-3 Filed February 6, 2023 File No. 333-269595 Dear Kathy Hibbs: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Daniel Crawford at 202-551-7767 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Alexandra Good, Esq.

Show Raw Text
United States securities and exchange commission logo
February 9, 2023
Kathy Hibbs
Chief Administrative Officer
23andMe Holding Co.
349 Oyster Point Boulevard
South San Francisco, California 94080
Re:23andMe Holding Co.
Registration Statement on Form S-3
Filed February 6, 2023
File No. 333-269595
Dear Kathy Hibbs:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Daniel Crawford at 202-551-7767 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Alexandra Good, Esq.